Difference between revisions of "Part:BBa K3142003"
 
(2 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
<partinfo>BBa_K3142003 short</partinfo>
 
<partinfo>BBa_K3142003 short</partinfo>
  
−
nisi&#25239;&#24615;&#22522;&#22240;&#65292;&#26159;&#19968;&#20010;&#39135;&#21697;&#32423;&#30340;&#25239;&#24615;&#31579;&#36873;&#22522;&#22240;&#65292;&#21487;&#20197;&#29992;&#26469;&#26500;&#24314;&#39135;&#21697;&#32423;&#36733;&#20307;&#65292;&#25105;&#20204;&#20351;&#29992;&#23427;&#26469;&#26367;&#25442;PMG36e&#20013;&#30340;&#32418;&#38665;&#25239;&#24615;
+
Much research has verified that tripeptides initiated with a branched-chain aliphatic amino acid residue and terminated with a proline have a strong antihypertensive activity in vivo. However, it is difficult to release from their precursor proteins that are orally administered. The dipeptides FR described here may be widely used as linkers to help the release of the active peptides with proline at C-terminus from their protein precursors by ACE or gastrointestinal enzymes in human body.
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here
Line 17: Line 17:
 
<partinfo>BBa_K3142003 parameters</partinfo>
 
<partinfo>BBa_K3142003 parameters</partinfo>
 
<!-- -->
 
<!-- -->
 +
===Reference===
 +
*Sheng-qi Rao, Song Liu, Tao Ju, et, al. Design of substrate-type ACE inhibitory pentapeptides with an antepenultimate C-terminal proline for efficient release of inhibitory activity.[J] Biochemical Engineering Journal. 60 (2012) 50– 55

Latest revision as of 16:43, 20 October 2019


FR

Much research has verified that tripeptides initiated with a branched-chain aliphatic amino acid residue and terminated with a proline have a strong antihypertensive activity in vivo. However, it is difficult to release from their precursor proteins that are orally administered. The dipeptides FR described here may be widely used as linkers to help the release of the active peptides with proline at C-terminus from their protein precursors by ACE or gastrointestinal enzymes in human body.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Reference

  • Sheng-qi Rao, Song Liu, Tao Ju, et, al. Design of substrate-type ACE inhibitory pentapeptides with an antepenultimate C-terminal proline for efficient release of inhibitory activity.[J] Biochemical Engineering Journal. 60 (2012) 50– 55